key: cord-1009702-dkcronri
authors: Cabaro, Serena; D’Esposito, Vittoria; Di Matola, Tiziana; Sale, Silvia; Cennamo, Michele; Terracciano, Daniela; Parisi, Valentina; Oriente, Francesco; Portella, Giuseppe; Beguinot, Francesco; Atripaldi, Luigi; Sansone, Mario; Formisano, Pietro
title: Cytokine signature and COVID-19 prediction models in the two waves of pandemics
date: 2021-10-21
journal: Sci Rep
DOI: 10.1038/s41598-021-00190-0
sha: ee16fe6fc726976b4de132f4f78f829926266862
doc_id: 1009702
cord_uid: dkcronri

In Europe, multiple waves of infections with SARS-CoV-2 (COVID-19) have been observed. Here, we have investigated whether common patterns of cytokines could be detected in individuals with mild and severe forms of COVID-19 in two pandemic waves, and whether machine learning approach could be useful to identify the best predictors. An increasing trend of multiple cytokines was observed in patients with mild or severe/critical symptoms of COVID-19, compared with healthy volunteers. Linear Discriminant Analysis (LDA) clearly recognized the three groups based on cytokine patterns. Classification and Regression Tree (CART) further indicated that IL-6 discriminated controls and COVID-19 patients, whilst IL-8 defined disease severity. During the second wave of pandemics, a less intense cytokine storm was observed, as compared with the first. IL-6 was the most robust predictor of infection and discriminated moderate COVID-19 patients from healthy controls, regardless of epidemic peak curve. Thus, serum cytokine patterns provide biomarkers useful for COVID-19 diagnosis and prognosis. Further definition of individual cytokines may allow to envision novel therapeutic options and pave the way to set up innovative diagnostic tools.

Since March 2020, a large number of studies on cytokine storm in COVID-19 patients has been published. Main findings often display a high degree of variability and refer to the first wave of the outbreak 11 . In this study, we have provided a cytokine profile of patients with mild and severe symptoms of COVID-19 during two peaks of epidemic curves in Campania region (Italy). Moreover, by using machine learning methods, we have analyzed whether a specific cytokine profile could guide disease diagnosis and prognosis.

Study design and ethics statement. Between March 2020 and May 2020, 65 consecutive patients with a positive SARS-CoV-2 PCR swab test, admitted at Federico II University Hospital and "Azienda Ospedaliera dei Colli" Hospital of Naples, Italy, were recruited for the study. 49 healthy adult volunteers were also enrolled as control cohort.

Similarly, during the second wave of pandemics, from September to October 2020, 36 patients with confirmed SARS-CoV-2 infection and 15 negative controls were included in the study.

The study was approved by the ethical committee of the University of Naples Federico II (prot. n. 140/20/ ESCOVID19). All the methods involving patients and volunteers have been performed in accordance with the Declaration of Helsinki. Also, an informed consent has been obtained from all participants.

Sample processing and cytokine assay. Blood Statistical analysis. A Shapiro-Wilk test was used to evaluate whether the continuous data were normal distributed, and according to the results, values were expressed as median and interquartile range and compared using the Kruskall-Wallis non-parametric test followed by Mann Whitney U test for pairwise comparisons. The non-parametric Jonckheere-Terpstra test was used to analyse trend between an ordinal independent variable. Categorical values were described by number of occurrences and percentages and compared by chi-square test.

Three machine learning methods have been used for prediction of COVID-19: linear discriminant analysis (LDA), classification and regression tree (CART) and neural network (NNET).Performance of algorithms in terms of sensitivity, specificity and overall accuracy were computed.

The predictive accuracy of the single factors and of the machine learning methods was measured by the area under the receiver operating characteristic (ROC) curve (AUC) 17 .

Algorithms have been first designed (trained) and then evaluated (test) on proper sets of data. To avoid overfitting and to robustly evaluate classification performance, a cross-validation approach was used. In detail, one of the subjects was excluded from the training set and used as test: the procedure was iterated over all the subjects and average performance were thus computed. Thisleave-one-out approach better suites for small data-sets 18, 19 :

Data from the first wave of outbreak have been used to produce cross-validated classifiers (LDA, CART): those classifiers have been then applied on data from the second wave. Performance have been evaluated using confusion matrix indices (sensitivity, specificity, overall accuracy).

Processing and statistical analysis have been conducted using R software. Differences were considered statistically significant for p value less than 0.05.

Wave 1 cytokine signature. Between March 2020 and May 2020, 65 patients with a positive SARS-CoV-2 PCR test were enrolled. In agreement with World Health Organization (WHO) eight-point scale for COVID-19 trial endpoints 20 , patients were classified in "mild" (WHO scores 3-4; N = 46) and "severe" (WHO scores 5-8; N = 19) . A cohort of 49 healthy blood donors was enrolled as control. No differences for gender were observed in the three groups (Table 1 ). Severe COVID-19 patients were significantly older compared with both mild COVID-19 patients and controls. At variance, no differences in age were detected between mild COVID-19 patients and controls (Table 1) .

A significant increasing trend of IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-15, IL-17, FGF-b, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, PDGF, TNF-α, and VEGF was observed in the three groups (Controls ≤ Mild COVID-19 ≤ Severe COVID-19) ( Table 1 , Fig. 1 ). Moreover, significantly higher concentration of all these factors was detected in serum of mild and severe COVID-19 patients compared to controls (Table 1) . Only FGF-b did not change between severe COVID-19 and controls (Table 1) . Finally, IL-1ra and IL-6 levels were significantly higher in severe versus mild COVID-19 patients, while PDGF decreased (Table 1) .

Thus, patients with COVID-19 displayed higher levels of cytokines and chemokines, as also shown by the starplot in Fig. 2 .

Cytokine-based prediction models. Next, we attempted to define a cytokine-based COVID-19 prediction model. As shown in Fig. 3 , LDA algorithm allowed to classify subjects in the three groups (control, mild COVID-19, severe COVID-19) with accuracy 0.96, 95% CI: (0.91, 0.99) (Fig. 3, Supplementary Tables 1-3 ). ROC analyses revealed that almost all cytokines could achieve high diagnostic discriminative power (Fig. 4) . Wave 2 cytokine signature. During September and October 2020 (wave 2), other 36 patients with confirmed SARS-CoV-2 infection and 15 negative controls were enrolled. 26 patients were classified as mild ad 10 patients as severe. As for wave 1, significant differences and increasing trends of IL-1β, IL-1ra, IL-2, IL-6, IL-8, IL-10, GM-CSF, IFN-γ, IP-10, were observed in the three groups (Controls ≤ Mild COVID-19 ≤ Severe COVID-19) ( Table 2 ). At variance, compared to wave 1, neither significant trend, neither significant difference was detected for IL-4, IL-5 IL-7, IL-17, FGF-b, G-CSF, PDGF, TNF-α, and VEGF among the three groups (Table 2) . Interestingly, in wave 2, only IL-1ra, IL-2, IL-6 IL-8 and IFN-γ concentrations were significantly higher in serum of mild and severe COVID-19 patients compared to controls (Table 2 ). Higher concentrations of IL-1β and IL-12(p70) were detected only in serum from mild COVID-19 patients, while IP-10 only in serum of severe COVID-19 patients, compared to controls ( Table 2) . Reduced levels of eotaxin in mild COVID-19 patients were also observed (Table 2) . Notably, compared to wave 1, only IP-10 concentrations were significantly higher in severe versus mild COVID-19 patients, with no change of IL-1ra and IL-6 levels ( Table 2) . algorithms defined with data of the first wave (Fig. 5) , CART analysis was carried out using data of the second wave as test sample. Test accuracy was 0.68; 95% CI: (0.54, 0.80), with a low sensitivity for the discrimination of severe COVID-19 and low specificity for mild COVID-19 patients (Supplementary Tables 7, 8) .

Thus, a prediction model was set up with cytokine data derived only from control and mild COVID-19 cohorts of wave 1. ROC analyses revealed that IL-5, IL-6, IL-7, IL-8 and IL-10 showed the best discriminative power (Supplementary Table 9 ). Based on these selected cytokines, CART algorithm indicated that IL-6 was able to discriminate control and mild COVID-19 patients with an overall test accuracy of 0.92; 95% CI: (0.85, 0.97) (Supplementary Tables 10, 11) . Interestingly, challenge of this prediction model with data from the second wave achieved an accuracy of 0.83; 95% CI: (0.68, 0.93), sensitivity of 0.88 and specificity of 0.73 (Supplementary  Tables 12, 13) , indicating IL-6 as the best predictor of COVID-19.

COVID-19, caused by the SARS-CoV-2, leads to fast activation of innate immune cells, with a profound cytokine response, especially in patients developing severe disease, resembling a hyper-inflammatory state 21 . The identification of specific cytokines as indicators of disease severity might improve clinical management of COVID-19 patients having a great impact on the diagnostic and therapeutic decision making. However, discrepancies exist on factors involved in cytokine storm and the majority of studies refers only to the first wave of outbreak.

Here, we have shown that: (1) second wave of COVID-19 pandemics is characterized by a less impressive cytokine storm compared to wave 1; (2) 27 cytokine-based algorithm allows to predict disease state and severity with an accuracy of about 96%; (3) IL-6 was significantly associated with COVID-19 diagnosis regardless of peak epidemic curve.

Accumulating evidence has clearly indicated that cytokine storm occurs in patients with COVID-19; however, the different cytokine profiles analyzed revealed variable results. Consistent with previous studies 12, 22 www.nature.com/scientificreports/ obtained in our population during the wave 1 reveal an activation of type 1, type 2 and type 3 immunity. In detail, we found increased levels of many pro-inflammatory and suppressive cytokines, as well as chemokines and growth factors, including IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-15, IL-17, FGF-b, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, PDGF, TNF-α, and VEGF. IL-6 and IL-1ra levels further increased in patients who were critically ill. It is widely recognized that IL-6, an important biomarker of inflammation for multiple conditions, has a crucial role in COVID-19 cytokine storm 23, 24 . Its levels correlate with serum viral load detected by RT-PCR in critically ill COVID-19 patients and with disease outcome [23] [24] [25] . IL-1ra has inhibitory roles against pro-inflammatory cytokine activation and T lymphocyte responses 26, 27 . It regulates IL-1, TNF-α and IFN production 27 , arguing a potential role in constraining a further increase of these cytokines in severe patients. The simultaneous increase of IL-6 and IL-1ra in critically ill patients suggests an overactive immune response, which may participate to the inflammation-induced tissue damage. Cytokines display a large interindividual variability, and their functions and release depend on multiple signals, different cell targets, physiological and lifestyle factors. Thus, it is particularly challenging to evaluate cytokines' diagnostic ability due to the difficulty of setting up cytokine cut-off levels 28, 29 . Notably, here we have shown that a 27-cytokine profiling could be used to stratify patients with COVID-19. However, currently, a diagnostic tool based on the measurement of the whole cytokinome may raise problems for high costs to the National Health Systems.

Thus, we selected IL-6, IL-8, IL-10 and IP-10 as the cytokines with the highest performance in the discrimination of mild COVID-19, severe COVID-19 patients and healthy volunteers. Our results are in agreement with the work by Laing and colleagues who identified IL-6, IL-10 and IP-10 as a "severity-related triad" 9 . IL-10 is a cytokine with anti-inflammatory functions. It suppresses macrophage and dendritic cell activation and limits Th1 and Th2 effector responses 28 . In COVID-19, IL-10 could be involved in counteracting the hyperactive immune response, thereby limiting injury but also boosting infection persistence. IP-10 has versatile biological functions www.nature.com/scientificreports/ on different cell types, which include chemoattraction of inflammatory cells, but also migration and proliferation of endothelial cells 30 . IP-10 is commonly secreted in response to IFNγ. However, it could be directly induced also by virus-related mechanisms 9 . IL-8 is a potent pro-inflammatory cytokine. It is involved in the recruitment and activation of neutrophils 31, 32 . Thus, its increase may be related to the neutrophilia often detected in patients with COVID-19. Interestingly, these four cytokines were fed into three machine learning methods: CART, NNET, and LDA. We found that all these methods were able to predict COVID-19 occurrence and severity with a comparable high performance. Although LDA and NNET provided superior or comparable accuracy, CART is considered the best performer regardless of sample size, group size ratio, effect size, and type of model and virtually always provides more accurate predictions. Moreover, CART, compared to the other prediction methods, provides the clinician with useful information regarding the relative importance of predictors in group separation with the advantage of producing human-readable rules 33 . Thus, we moved on to CART algorithm and found that IL-6 is the best predictor for COVID-19 disease. The addition of IL-8 well defined disease severity.

However, to obtain a best validation of the algorithm, we challenged the method with the determination of serum cytokines of patients enrolled in a different epidemic peak.

Characteristics of patients with COVID-19 have largely changed over time [3] [4] [5] . In Italy, patients who died in the second phase of the epidemic were older, more likely to be women, and had higher probability of superinfections, larger comorbidity burden, and longer survival from symptom onset compared to people who died in the first phase (March-May 2020) 5 . Here, we found that in wave 2 the cytokine storm profile developed at lower levels, www.nature.com/scientificreports/ compared to wave 1. Many cytokines that during wave 1 were increased in serum of COVID-19 patients were undistinguishable in patients compared to controls, during wave 2. For example, IL-4 and IL-5 levels were not increased in wave 2 COVID-19 patients, suggesting lack of type 2 immunity activation. Moreover, in comparison to wave 1, only IP-10 levels were significantly higher in severe versus mild COVID-19 patients, with no change of IL-1ra and IL-6 levels. IP-10 increase was not paralleled by IFN-γ increase, suggesting a direct relationship with viral pathogenic mechanisms.

The treatment approach has changed over the two periods, as critically ill patients in the second phase were less likely to receive antivirals and/or IL-6R inhibitors and more likely to be treated with steroids and FANS. Thus, the reduction of cytokine storm extent observed in wave 2 may reflect the different therapeutic strategies adopted in the two epidemic moments. For instance, in wave 2, the loss of IL-6 augmentation in severe COVID-19 may be explained with the treatment approach, definitely not based on tocilizumab administration.

The discrepancies we found among cytokine profiles in the two COVID-19 outbreaks has led to a modification of discriminative power of the previously identified algorithm. In particular, the challenge of the method with the results obtained during the second wave has revealed a different pattern of cytokines with best predictive performance and a reduction in the classification between mild and severe COVID-19. However, CART analysis was still able to define controls and mild COVID-19 patients, with high accuracy by an algorithm based on IL-6 concentration. Thereby, we have confirmed that IL-6 remains an excellent predictor and found that it represents a COVID-19 biomarker regardless the epidemic peak curves.

In conclusion, it is conceivable that a detailed knowledge of the role of single cytokines in SARS-CoV-2 infection and a prediction model built on cytokine levels might strongly help to foster novel diagnostic tools and to inform innovative therapeutic interventions. . The decision tree shows the rules and split points to estimate COVID-19 disease and severity. In each box, the first number estimates controls, the second number estimates mild COVID-19 patients, the third number severe COVID-19 patients. Decision binary tree reveals an optimal cut-off of IL-6 > 6.8 pg/ml for predicting COVID-19 disease and of IL-8 > 117 pg/ml for severity (C). 

The novel coronavirus originating in Wuhan, China: Challenges for global health governance

Clinical characteristics of coronavirus disease 2019 in China

Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: No prognostic improvement during the second wave?

Epidemiologic comparison of the first and second waves of coronavirus disease in Babol, North of Iran

Differences in the clinical characteristics of COVID-19 patients who died in hospital during different phases of the pandemic: National data from Italy

First and second COVID-19 waves in Japan: A comparison of disease severity and characteristics

Cytokine release syndrome in severe COVID-19

Covid-19-associated coagulopathy: Biomarkers of thrombin generation and fibrinolysis leading the outcome

A dynamic COVID-19 immune signature includes associations with poor prognosis

Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection

COVID-19: In the eye of the cytokine storm

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: The REPROGRAM consortium position paper

The trinity of COVID-19: Immunity, inflammation and intervention

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts

White cell and platelet content affects the release of bioactive factors in different blood-derived scaffolds

Prostate health index (Phi) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml

Pattern Recognition and Neural Networks

Modern applied statistics with S-PLUS

COVID-19 Therapeutic Trial Synopsis

COVID-19: Risk for cytokine targeting in chronic inflammatory diseases?

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Elevated interleukin-6 and severe COVID-19: A meta-analysis

An inflammatory cytokine signature predicts COVID-19 severity and survival

Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019

Imbalance between interleukin-1beta and interleukin-1 receptor antagonist in epicardial adipose tissue is associated with non ST-segment elevation acute coronary syndrome

Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease

Cytokine profiles before and after immune modulation in hospitalized patients with COVID-19

Cytokines as biomarkers and their respective clinical cutoff levels

The multifaceted functions of CXCL10 in cardiovascular disease

Glucose impairs tamoxifen responsiveness modulating connective tissue growth factor in breast cancer cells

Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils

A comparison of two-group classification methods

This work was supported by the Regione Campania POR FESR 2014-2020-Objective 1.2.-Realization of Technology Platform to fight oncologic diseases (RARE PLAT NET, SATIN, and COEPICA Projects) to F.B. and P.F., by the Italian Association for the Cancer Research-AIRC (grant IG19001) to P.F., and by University of Naples Federico II and "Compagnia di San Paolo e Istituto Banco di Napoli" STAR 2018 grant to V.P.

S.C. and V.D'E. were the main contributors in terms of conception, design, acquisition and interpretation of data, and in drafting the manuscript. T.D.M., S.S. and L.A. enrolled the patients and organized patient data. M.C., D.T., G.P enrolled the patients and organized database, V.P and F.O. contributed in terms of conceptual design. F.B., V.P. and P.F. contributed for funding acquisition. M.S. performed the statistical analysis. P.F. contributed in terms of conceptual design, interpretation and discussion of the results, and supervision of the overall work. All authors have approved the submitted version.

The authors declare no competing interests.

Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-021-00190-0.Correspondence and requests for materials should be addressed to P.F.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.